Merck & Co., Inc.MRK

Healthcare
Neutral

ASignal's systematic analysis rates MRK as Neutral. Merck & Co., Inc. has a market cap of $306.33B, a P/E of 34.94, a 13.6% net margin, and 4.9% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jul 16, 2026

The case on MRK

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Strong gross margin (76.73%) indicating pricing power
  • Operating cash flow of $17.89B supports core operations
  • Free cash flow of $14.05B provides financial flexibility
  • Return on equity (18.94%) above 15%, signaling solid capital efficiency
  • Forward P/E of 12.94x is below current P/E, suggesting earnings growth expectations
VS
Bear case
  • Debt-to-equity ratio of 1.07x, above the 1.0 threshold, indicating high leverage
  • High dividend payout ratio (93.52%) raises sustainability concerns
  • RSI at 63.05 — approaching overbought territory
  • MACD histogram is negative (-0.329), signaling weakening bullish momentum
  • Price near upper Bollinger Band (133.81), suggesting potential resistance
  • Low quick ratio (0.70x) indicates potential liquidity pressure

Key facts

Sector
Healthcare
Market cap
$306.33B
P/E ratio
34.94
Gross margin
76.7%
Net margin
13.6%
Rev growth YoY
4.9%
Price (Jul 14, 2026)
$124.03

Peers

Clustered with MRK by analysis-profile similarity.

Subscriber-only

See the full verdict on MRK

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes MRK

Most investors never get a second opinion, let alone several. ASignal runs MRK past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Merck & Co., Inc. (MRK) Stock Analysis - ASignal rates it Neutral